Home / Stocks / Unichem Laboratories Ltd
UNICHEMLAB

Unichem Laboratories Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹479.25

Change

+0.15 (0.03%)

Open

₹478.0

Prev. Close

₹479.1

Day High

₹484.8

Day Low

₹474.0

Volume Analysis

Traded

12,709

Delivered

5,224

Delivery %

41.1%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Low return on equity (3.17%)

Opportunities (2)

  • •Strong 3-year revenue growth (17.9%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹495.5 ₹490.15 ₹484.7 ₹479.35 ₹473.9 ₹468.55 ₹463.1
Fibonacci ₹490.15 ₹486.02 ₹483.48 ₹479.35 ₹475.22 ₹472.68 ₹468.55
Camarilla ₹482.22 ₹481.23 ₹480.24 ₹479.35 ₹478.26 ₹477.27 ₹476.28

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+8.95%

1 Week

-3.59%

1 Month

-5.03%

3 Months

-8.91%

6 Months

+29.23%

1 Year

+0.21%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹564.93

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.3%

Net margin 14.31% × asset turnover 0.56x × equity multiplier 1.41x

Company Overview

Sector

Healthcare

Market Cap

₹3,511 Cr

P/E (TTM)

29.5

ROE

3.17%

Book Value

₹395.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Unichem Laboratories Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 57/100. The strongest factor is Financial Strength (100/100), while Liquidity (23/100) is the weakest area to weigh before deciding. Notably: Low return on equity (3.17%). Strong 3-year revenue growth (17.9%).

TopFund Score — Fundamentals Quality

57/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

83

Valuation

60

Cash Flow

25

Corporate Governance

56

Momentum

54

Institutional Ownership

39

Business Quality

48

Risk & Volatility

45

Liquidity

23

From Screener.in

  • +Company has delivered good profit growth of 25.0% CAGR over last 5 years
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 2.34% over last 3 years.
  • −Earnings include an other income of Rs.305 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Publication of Financial Results for quarter and half year ended September 30, 2026, in newspapers.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 416 466 432 483 507 533 587 527 579 521 575 633 640
Expenses + 407 435 406 443 452 448 503 504 513 476 527 563 566
Operating Profit 9 31 25 40 55 86 84 22 66 45 48 70 74
OPM % 2.1% 7.0% 6.0% 8.0% 11.0% 16.0% 14.0% 4.3% 11.0% 9.0% 8.0% 11.0% 12.0%
Other Income + 6 79 -119 4 9 14 9 7 -37 287 11 16 -9
Interest 7 6 5 4 5 7 5 7 8 7 9 7 8
Depreciation 29 32 27 32 32 31 30 32 31 31 31 30 30
Profit before tax -22 73 -126 8 27 62 58 -9 -11 293 19 49 27
Tax % 12.0% 0.0% 3.0% 74.0% 9.0% 6.0% 8.0% 16.0% 10.0% 10.0% 42.0% 15.0% 19.0%
Net Profit + -24 73 -129 2 25 58 53 -10 -12 264 11 41 22
EPS in Rs -3 10 -18 0 4 8 8 -1 -2 38 2 6 3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 26 54 7 14 22 14 36 9 14 -2 -2 20 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,202 1,333 698 815 1,180 1,104 1,235 1,270 1,343 1,785 2,111 2,202 2,369
Expenses + 1,100 1,169 738 942 1,254 1,153 1,144 1,198 1,389 1,698 1,846 2,013 2,132
Operating Profit 101 164 -41 -128 -74 -49 91 72 -46 87 265 189 237
OPM % 8.0% 12.0% -6.0% -16.0% -6.0% -4.5% 7.0% 6.0% -3.4% 4.9% 13.0% 9.0% 10.0%
Other Income + 20 15 184 2,735 91 91 50 47 0 -26 35 260 305
Interest 3 3 3 8 8 8 5 6 17 23 21 32 31
Depreciation 41 39 44 51 67 82 84 91 113 123 125 125 122
Profit before tax 77 137 97 2,548 -58 -48 51 22 -176 -85 155 292 389
Tax % 3.0% 21.0% -12.0% 0.0% -59.0% 25.0% 33.0% -50.0% 15.0% 10.0% 11.0% 14.0% —
Net Profit + 75 108 109 2,545 -24 -60 34 33 -202 -94 138 253 339
EPS in Rs 8 12 12 362 -3 -9 5 5 -29 -13 20 36 48
Dividend Payout % 24.0% 17.0% 25.0% 1.0% -118.0% -47.0% 82.0% 85.0% -14.0% 0.0% 0.0% 0.0% —
Sales growth 6 11 -48 17 45 -6 12 3 6 33 18 4 6

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 849 936 1,045 2,666 2,606 2,517 2,543 2,604 2,421 2,424 2,437 2,703 2,767
Borrowings + 22 36 98 151 200 206 119 349 314 248 460 500 498
Other Liabilities + 264 283 359 359 323 407 436 351 444 589 659 489 628
Total Liabilities 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,275 3,569 3,707 3,908
Fixed Assets + 416 403 491 578 810 870 884 990 1,257 1,252 1,300 1,213 1,170
CWIP 123 237 250 238 92 330 568 494 147 123 31 100 126
Investments 41 14 14 901 926 550 392 264 2 1 0 0 0
Other Assets + 574 620 766 1,473 1,313 1,395 1,269 1,571 1,787 1,898 2,239 2,394 2,612
Total Assets 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,275 3,569 3,707 3,908
Equity Capital 18 18 18 14 14 14 14 14 14 14 14 14 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 78 112 68 -112 -328 20 33 -260 -85 14 -7 4
Cash from Investing Activity + -52 -85 -132 1,648 -286 -36 -66 100 241 63 -242 194
Cash from Financing Activity + -51 -33 59 -881 -2 -62 -121 191 -81 -106 184 2
Net Cash Flow -25 -7 -4 655 -616 -78 -154 32 75 -29 -65 200
Free Cash Flow 4 -28 -79 -271 -519 -360 -254 -386 -123 0 -142 163
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 95 87 -237 89 424 -49 52 -350 160 23 4 6

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.22% → 70.22%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 18.47% 17.63% 17.32% 17.17% 17.11% 17.47% 17.88% 18.04% 18.05% 18.14% 18.41% 17.67%
Promoters 70.22% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22%
FII 0.84% 0.9% 0.89% 0.94% 1.05% 0.98% 0.98% 0.99% 0.99% 1.0% 0.9% 2.7%
DII 10.46% 11.26% 11.57% 11.65% 11.63% 11.32% 10.92% 10.74% 10.73% 10.63% 10.46% 9.4%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Unichem Laboratories Ltd (this stock) 3,511 29.5 1.26 3.17%
Shukra Pharmaceuticals L 3,639 82.1 30.56 28.9%
Solara Active Pha Sci Ltd 3,347 70.7 2.33 -0.13%
Advanced Enzyme Tech Ltd 3,102 19.1 1.9 10.5%
Ind Swift Laboratories Lt 2,881 31.4 1.95 4.02%
Rpg Life Sciences Ltd 4,220 36.8 6.13 19.3%
Hikal Limited 2,690 37.8 2.28 2.21%

Which Mutual Funds Hold Unichem Laboratories Ltd?

Frequently Asked Questions about Unichem Laboratories Ltd

Community Sentiment

What are other investors saying about Unichem Laboratories Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.